iRhythm Holdings (IRTC) Net Income towards Common Stockholders (2015 - 2026)
iRhythm Holdings' (IRTC) quarterly Net Income towards Common Stockholders came in at -$13.9 million in Q1 2026, up 54.62% year-on-year from -$9.0 million in Q1 2025, and down 349.74% on a QoQ basis from $5.6 million in Q4 2025.
iRhythm Holdings (IRTC) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
iRhythm Holdings (IRTC) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$13.9 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 54.62% year-over-year to -$13.9 million in Q1 2026; TTM through Mar 2026 was -$27.8 million, a 71.74% increase from a year earlier, with the FY2025 full-year figure at -$44.6 million, up 60.67% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$13.9 million, down from $5.6 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for IRTC reached as high as $5.6 million in Q4 2025 and fell as low as -$50.6 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$24.2 million across 5 years, with a median of -$21.5 million in 2022.
- Across the five-year window, Net Income towards Common Stockholders tumbled 91.6% in 2023 and soared 518.53% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$20.2 million in 2022, then tumbled by 91.6% to -$38.7 million in 2023, then soared by 96.56% to -$1.3 million in 2024, then surged by 518.53% to $5.6 million in 2025, then tumbled by 349.74% to -$13.9 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$13.9 million in Q1 2026, $5.6 million in Q4 2025, and -$5.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | iRhythm Holdings | 3.65 Bn | 3.10 Bn | 141.35 Mn | -13.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.93 Mn |
| Dec 31, 2025 | 5.58 Mn |
| Sep 30, 2025 | -5.21 Mn |
| Jun 30, 2025 | -14.22 Mn |
| Mar 31, 2025 | -30.70 Mn |
| Dec 31, 2024 | -1.33 Mn |
| Sep 30, 2024 | -46.18 Mn |
| Jun 30, 2024 | -20.11 Mn |
| Mar 31, 2024 | -45.67 Mn |
| Dec 31, 2023 | -38.70 Mn |
| Sep 30, 2023 | -27.12 Mn |
| Jun 30, 2023 | -18.48 Mn |
| Mar 31, 2023 | -39.11 Mn |
| Dec 31, 2022 | -20.20 Mn |
| Sep 30, 2022 | -21.45 Mn |
| Jun 30, 2022 | -23.90 Mn |
| Mar 31, 2022 | -50.61 Mn |
| Dec 31, 2021 | -32.49 Mn |
| Sep 30, 2021 | -23.73 Mn |
| Jun 30, 2021 | -17.36 Mn |